Biorestorative Therapies, Inc. (NASDAQ:BRTX) Sees Large Drop in Short Interest

Biorestorative Therapies, Inc. (NASDAQ:BRTX) was the target of a significant drop in short interest during the month of July. As of July 31st, there was short interest totaling 463,966 shares, a drop of 39.9% from the July 15th total of 772,008 shares. Based on an average daily trading volume, of 430,028 shares, the short-interest ratio is currently 1.1 days. Approximately 2.1% of the company’s shares are sold short.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Biorestorative Therapies in a report on Wednesday, May 27th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Biorestorative Therapies has an average rating of “Sell”.

Biorestorative Therapies Stock Performance

Shares of BRTX stock traded down $0.00 during trading hours on Tuesday, hitting $0.22. 89,264 shares of the company were exchanged, compared to its average volume of 7,923,660. The firm has a market cap of $5.53 million, a P/E ratio of -0.20 and a beta of 0.79. Biorestorative Therapies has a fifty-two week low of $0.16 and a fifty-two week high of $1.89. The company has a 50 day simple moving average of $0.32 and a two-hundred day simple moving average of $0.34.

Hedge Funds Weigh In On Biorestorative Therapies

Several institutional investors have recently made changes to their positions in the stock. DRW Securities LLC bought a new position in shares of Biorestorative Therapies during the 4th quarter worth about $55,000. Citadel Advisors LLC bought a new stake in Biorestorative Therapies in the 3rd quarter valued at about $152,000. Finally, Virtu Financial LLC raised its stake in Biorestorative Therapies by 102.4% during the 3rd quarter. Virtu Financial LLC now owns 24,351 shares of the company’s stock worth $35,000 after buying an additional 12,319 shares during the period. Institutional investors and hedge funds own 69.38% of the company’s stock.

About Biorestorative Therapies

Biorestorative Therapies Inc (NASDAQ: BRTX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of regenerative tissue therapy products. The company leverages a proprietary universal allogeneic cell technology platform to create high-potency cell therapy candidates designed to promote tissue repair, reduce inflammation and accelerate healing in areas damaged by disease or medical treatment.

Its lead development program targets radiation-induced oral mucositis (RIOM), a painful and dose-limiting side effect experienced by head and neck cancer patients undergoing radiotherapy.